Editing Daiichi Sankyo Company, Limited (section)

{{Infobox company
|name          = Daiichi Sankyo Company, Limited
|logo          = Daiichi_Sankyo_logo.svg
|logo_size     = 175px
| native_name  = 第一三共株式会社
| native_name_lang = ja
| romanized_name = Daiichi Sankyō kabushiki gaisha
|type          = [[Public company|Public]] [[Kabushiki gaisha|KK]]
|traded_as     = {{TYO|4568}}<br>[[TOPIX|TOPIX Large 70 Component]]<br>[[TOPIX|TOPIX 100 Component]]<br>[[Nikkei 225|Nikkei 225 Component]]
|foundation    = [[Tokyo]], [[Japan]] ({{Start date and age|2005}}) (by merger)
|predecessors  = {{unbulleted list|Daiichi Pharmaceutical Company|Sankyo Company}}
|location      = Daiichi Sankyo Building A/B 3-5-1, [[Nihonbashi, Tokyo|Nihonbashi-honcho]], [[Chūō, Tokyo|Chūō-ku]], [[Tokyo]] 103-8426, [[Japan]]
|key_people    = {{unbulleted list|Sunao Manabe (Representative Director,  and [[President (corporate title)|President]])<ref>{{cite news |title=Daiichi Sankyo name current COO Sunao Manabe as firm's new CEO |url=http://www.pharmafile.com/appointment/521180/daiichi-sankyo-name-current-coo-sunao-manabe-firms-new-ceo |access-date=12 November 2020 |work=Pharmafile |date=4 December 2019}}</ref><ref>{{cite web |title=Message from Our CEO |url=https://www.daiichisankyo.com/about_us/mission-strength/top_message/ |website=Daiichi Sankyo |access-date=12 November 2020}}</ref>|Ken Keller (President and CEO, Daiichi Sankyo, Inc.)<ref>{{cite web |title=Corporate Management Information – Ken Keller |url=https://dsi.com/ken-keller |website=Daiichi Sankyo, Inc. |access-date=30 November 2020}}</ref>}}
|num_employees = 17,435 (2023)
|products      = {{unbulleted list|[[Medical equipment]]|[[Pharmaceutical]] products }}
|homepage      = http://www.daiichisankyo.com
|industry      = [[Pharmaceutical company|Pharmaceutical]]
|revenue       = {{profit}} $ 9.015 billion [[US dollar|USD]] ([[Fiscal year|FY]] 2023)
                             (¥  1.28 trillion [[Japanese yen|JPY]]) ([[Fiscal year|FY]] 2023)
|net_income    = {{profit}} $ 769.3 million [[US dollar|USD]] ([[Fiscal year|FY]] 2023)
                             (¥  109.1 billion [[Japanese yen|JPY]]) ([[Fiscal year|FY]] 2023)
|footnotes     =<ref>{{cite news |title=Value Report 2020 |url=https://www.daiichisankyo.com/files/investors/library/annual_report/index/pdf/2020_VR/Value%20Report%202020%20EN.pdf |access-date=30 November 2020 |work=Daiichi Sankyo Group |date=31 March 2020 |page=45}}</ref>
}}

Daiichi Sankyo Company, a Tokyo-based global pharmaceutical leader, operates across various sectors of the medical industry, providing an extensive portfolio of treatments for a wide range of conditions.

In the cancer domain, they offer innovative treatments like trastuzumab deruxtecan, gefitinib, bicalutamide, and tamoxifen. They also provide drugs for pain management, neurological disorders, such as Alzheimer's, and epilepsy.

Their diabetes and heart disease portfolio includes products like teneligliptin, canagliflozin, pravastatin, and edoxaban, while their gastrointestinal and infectious disease lineups offer treatments like esomeprazole and vaccines for various conditions.

Daiichi Sankyo also contributes to the skincare and oral care sectors with products such as Transino and Breath Labo. Their range even extends to over-the-counter medicines, animal healthcare products, cosmetics, medical equipment, and food products.

In a partnership with Guardant Health, they are developing a companion diagnostic for a lung cancer treatment. Founded in 1899, Daiichi Sankyo's legacy of innovation continues to shape the global pharmaceutical landscape.